

# Alexandre R Zlotta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8289580/publications.pdf>

Version: 2024-02-01

213  
papers

10,468  
citations

34105

52  
h-index

38395

95  
g-index

223  
all docs

223  
docs citations

223  
times ranked

9615  
citing authors

#	ARTICLE	IF	CITATIONS
1	Combining CAPRA-S With Tumor IDC/C Features Improves the Prognostication of Biochemical Recurrence in Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e217-e226.	1.9	3
2	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, 40, 110.e1-110.e9.	1.6	22
3	The prognostic value of urinary cytology after trimodal therapy (TMT) for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2022, , .	1.6	0
4	Prostate biopsy in the era of MRI-targeting: towards a judicious use of additional systematic biopsy. <i>European Radiology</i> , 2022, 32, 7544-7554.	4.5	8
5	T1G1 Bladder Cancer: Prognosis for this Rare Pathological Diagnosis Within the Non-muscle-invasive Bladder Cancer Spectrum. <i>European Urology Focus</i> , 2022, , .	3.1	4
6	A semi-supervised learning approach for bladder cancer grading. <i>Machine Learning With Applications</i> , 2022, 9, 100347.	4.4	7
7	Switching Cancers: A Systematic Review Assessing the Role of Androgen Suppressive Therapy in Bladder Cancer. <i>European Urology Focus</i> , 2021, 7, 1044-1051.	3.1	13
8	Natural History of Renal Angiomyolipoma Favors Surveillance as an Initial Approach. <i>European Urology Focus</i> , 2021, 7, 582-588.	3.1	10
9	Novel use of an old compound? Urologist-led Bacille Calmette-Guérin vaccine trials in the prevention of coronavirus disease 2019. <i>BJU International</i> , 2021, 127, 35-36.	2.5	0
10	Benefit of a more extended pelvic lymph node dissection among patients undergoing radical prostatectomy for localized prostate cancer: A causal mediation analysis. <i>Prostate</i> , 2021, 81, 286-294.	2.3	4
11	MRI-guided Focused Ultrasound Ablation for Localized Intermediate-Risk Prostate Cancer: Early Results of a Phase II Trial. <i>Radiology</i> , 2021, 298, 695-703.	7.3	33
12	Canadian Urological Association guideline on the management of non-muscle invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2021, 15, E424-E460.	0.6	7
13	European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel. <i>European Urology</i> , 2021, 79, 480-488.	1.9	198
14	Prognostic Value of the WHO1973 and WHO2004/2016 Classification Systems for Grade in Primary Ta/T1 Non-muscle-invasive Bladder Cancer: A Multicenter European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel Study. <i>European Urology Oncology</i> , 2021, 4, 182-191.	5.4	54
15	Characterization and management of NMIBC recurrences after TMT: a matched cohort analysis. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 835.e1-835.e7.	1.6	3
16	100 years of Bacillus Calmette-Guérin immunotherapy: from cattle to COVID-19. <i>Nature Reviews Urology</i> , 2021, 18, 611-622.	3.8	80
17	Clinicopathologic factors that influence prognosis and survival outcomes in men with metastatic castration-resistant prostate cancer treated with Radium-223. <i>Cancer Medicine</i> , 2021, 10, 5775-5782.	2.8	7
18	Avoiding Unnecessary Biopsy: MRI-based Risk Models versus a PI-RADS and PSA Density Strategy for Clinically Significant Prostate Cancer. <i>Radiology</i> , 2021, 300, 369-379.	7.3	34

#	ARTICLE	IF	CITATIONS
19	Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer – Abridged version. Canadian Urological Association Journal, 2021, 15, 230-9.	0.6	8
20	Curative-intent Metastasis-directed Therapies for Molecularly-defined Oligorecurrent Prostate Cancer: A Prospective Phase II Trial Testing the Oligometastasis Hypothesis. European Urology, 2021, 80, 374-382.	1.9	49
21	Somatic driver mutation prevalence in 1844 prostate cancers identifies ZNRF3 loss as a predictor of metastatic relapse. Nature Communications, 2021, 12, 6248.	12.8	15
22	Trimodal therapy vs. radical cystectomy for muscle-invasive bladder cancer: A Markov microsimulation model. Canadian Urological Association Journal, 2021, 16, .	0.6	3
23	Genomic characterization of non-schistosomiasis-related squamous cell carcinoma of the urinary bladder: A retrospective exploratory study. PLoS ONE, 2021, 16, e0259272.	2.5	4
24	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. European Urology, 2020, 77, 420-433.	1.9	741
25	Methylation Markers in Prostate Biopsies Are Prognosticators for Late Biochemical Recurrence and Therapy after Surgery in Prostate Cancer Patients. Journal of Molecular Diagnostics, 2020, 22, 30-39.	2.8	3
26	An integrative DNA methylation model for improved prognostication of postsurgery recurrence and therapy in prostate cancer patients. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 39.e1-39.e9.	1.6	9
27	Papillary urothelial neoplasm of low malignant potential (PUN-LMP): Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019?. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 440-448.	1.6	27
28	Salvage radical prostatectomy following focal therapy: functional and oncological outcomes. BJU International, 2020, 125, 525-530.	2.5	21
29	Re: Reconsidering Prostate Cancer Mortality - The Future of PSA Screening. European Urology, 2020, 78, 927-929.	1.9	2
30	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment? – European Urology, 2020, 78, 682-687.	1.9	57
31	Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 850.e9-850.e15.	1.6	17
32	Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not. European Urology Open Science, 2020, 22, 61-73.	0.4	11
33	Canadian experience of neoadjuvant chemotherapy on bladder recurrences in patients managed with trimodal therapy for muscle-invasive bladder cancer. Canadian Urological Association Journal, 2020, 14, 404-410.	0.6	3
34	Re: Artificial Intelligence for Diagnosis and Grading of Prostate Cancer in Biopsies: A Population-based, Diagnostic Study. European Urology, 2020, 78, 290-291.	1.9	4
35	A noninvasive urine-based methylation biomarker panel to detect bladder cancer and discriminate cancer grade. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 603.e1-603.e7.	1.6	13
36	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. Eur Urol 2020;77:434–5. European Urology, 2020, 77, 436-438.	1.9	1

#	ARTICLE	IF	CITATIONS
37	Does Time Spent on Active Surveillance Adversely Affect the Pathological and Oncologic Outcomes in Patients Undergoing Delayed Radical Prostatectomy?. <i>Journal of Urology</i> , 2020, 204, 476-482.	0.4	7
38	A Prospective Randomized Controlled Trial of Irrigation "Bag Squeeze" to Manage Pain for Patients Undergoing Flexible Cystoscopy. <i>Journal of Urology</i> , 2020, 204, 1012-1018.	0.4	9
39	Primary analysis of a phase II study of metastasis-directed ablative therapy to PSMA (<sup>18</sup>F-DCFPyL) PET-MR/CT defined oligorecurrent prostate cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 5553-5553.	1.6	1
40	Trimodal therapy in muscle invasive bladder cancer management. <i>Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology</i> , 2020, 72, 650-662.	3.9	8
41	Lynch Syndrome in Urologic Malignancies " What Does the Urologist Need to Know?. <i>Urology</i> , 2019, 134, 24-31.	1.0	10
42	Are there differences among Bacillus Calmette-Guérin (BCG) strains regarding their clinical efficacy in the treatment of non-muscle invasive bladder cancer? The jury is still out but the answer is likely no. <i>Canadian Urological Association Journal</i> , 2019, 14, E54-E56.	0.6	1
43	Systematic review and meta-analysis on trimodal therapy versus radical cystectomy for muscle-invasive bladder cancer: Does the current quality of evidence justify definitive conclusions?. <i>PLoS ONE</i> , 2019, 14, e0216255.	2.5	17
44	The use of intravesical BCG in urothelial carcinoma of the bladder. <i>Ecancermedalscience</i> , 2019, 13, 905.	1.1	46
45	Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression. <i>Clinical Epigenetics</i> , 2019, 11, 54.	4.1	20
46	A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 61-66.	0.8	8
47	Are there differences between de novo and secondary upper tract urothelial carcinoma tumours?. <i>Canadian Urological Association Journal</i> , 2019, 13, E292-E299.	0.6	0
48	Further Evidence of Differences in Prostate Cancer Biomarkers Between Caucasian and Asian Men. <i>European Urology</i> , 2019, 75, 562-563.	1.9	3
49	Combined genetic and epigenetic alterations of the <i>TERT</i> promoter affect clinical and biological behavior of bladder cancer. <i>International Journal of Cancer</i> , 2019, 144, 1676-1684.	5.1	57
50	Neoadjuvant Chemotherapy Before Bladder-Sparing Chemoradiotherapy in Patients With Nonmetastatic Muscle-Invasive Bladder Cancer. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 38-45.	1.9	29
51	Comprehensive Imaging and Surgical Review of Urinary Diversions: What the Radiologist Needs to Know. <i>Current Problems in Diagnostic Radiology</i> , 2019, 48, 161-171.	1.4	5
52	Risk of Bone Fractures Following Urinary Intestinal Diversion: A Population Based Study. <i>Journal of Urology</i> , 2019, 202, 319-325.	0.4	5
53	Reply by Authors. <i>Journal of Urology</i> , 2019, 202, 325-325.	0.4	0
54	Understanding how prostate cancer patients value the current treatment options for metastatic castration resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 240.e13-240.e20.	1.6	7

#	ARTICLE	IF	CITATIONS
55	The World Health Organization 1973 classification system for grade is an important prognosticator in T1 non-muscle-invasive bladder cancer. <i>BJU International</i> , 2018, 122, 978-985.	2.5	25
56	Defining a Cohort that May Not Require Repeat Prostate Biopsy Based on PCA3 Score and Magnetic Resonance Imaging: The Dual Negative Effect. <i>Journal of Urology</i> , 2018, 199, 1182-1187.	0.4	22
57	Magnetic resonance guided focused high frequency ultrasound ablation for focal therapy in prostate cancer – phase 1 trial. <i>European Radiology</i> , 2018, 28, 4281-4287.	4.5	30
58	The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. <i>European Urology</i> , 2018, 73, 543-557.	1.9	105
59	Canadian Urological Association guideline: Muscle-invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2018, 13, 230-238.	0.6	51
60	A novel predictor of clinical progression in patients on active surveillance for prostate cancer. <i>Canadian Urological Association Journal</i> , 2018, 13, 250-255.	0.6	3
61	Molecular Characterization of Bladder Cancer. <i>Current Urology Reports</i> , 2018, 19, 107.	2.2	10
62	Replacing surveillance cystoscopy with urinary biomarkers in followup of patients with non-muscle-invasive bladder cancer: Patients' and urologic oncologists' perspectives. <i>Canadian Urological Association Journal</i> , 2018, 12, E210-8.	0.6	7
63	A feed forward loop enforces YAP/TAZ signaling during tumorigenesis. <i>Nature Communications</i> , 2018, 9, 3510.	12.8	75
64	Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2018, 36, 361.e7-361.e13.	1.6	20
65	Evaluation of an Aggressive Prostate Biopsy Strategy in Men Younger than 50 Years. <i>Journal of Urology</i> , 2018, 200, 1056-1061.	0.4	2
66	Editorial Comment. <i>Journal of Urology</i> , 2018, 199, 967-967.	0.4	0
67	Impact of oral hypoglycemic agents on mortality among diabetic patients with non-muscle-invasive bladder cancer: A population-based analysis. <i>Canadian Urological Association Journal</i> , 2018, 12, 203-10.	0.6	6
68	Statin use and time to progression in men on active surveillance for prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2018, 21, 509-515.	3.9	7
69	Epigenome-Wide DNA Methylation Profiling Identifies Differential Methylation Biomarkers in High-Grade Bladder Cancer. <i>Translational Oncology</i> , 2017, 10, 168-177.	3.7	29
70	Germline Mutations in the Kallikrein 6 Region and Predisposition for Aggressive Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	13
71	Development and external validation of a biopsy-derived nomogram to predict risk of ipsilateral extraprostatic extension. <i>BJU International</i> , 2017, 120, 76-82.	2.5	23
72	Creation and internal validation of a biopsy avoidance prediction tool to aid in the choice of diagnostic approach in patients with prostate cancer suspicion. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2017, 35, 604.e17-604.e24.	1.6	2

#	ARTICLE	IF	CITATIONS
73	A Phase II, Randomized, Open-Label Study of Neoadjuvant Degarelix versus LHRH Agonist in Prostate Cancer Patients Prior to Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2017, 23, 1974-1980.	7.0	37
74	Urinary DNA Methylation Biomarkers for Noninvasive Prediction of Aggressive Disease in Patients with Prostate Cancer on Active Surveillance. <i>Journal of Urology</i> , 2017, 197, 335-341.	0.4	39
75	Limitations in Predicting Organ Confined Prostate Cancer in Patients with Gleason Pattern 4 on Biopsy: Implications for Active Surveillance. <i>Journal of Urology</i> , 2017, 197, 75-83.	0.4	39
76	What false-negative rates of non-invasive testing are active surveillance patients and uro-oncologists willing to accept in order to avoid prostate biopsy?. <i>Canadian Urological Association Journal</i> , 2017, 11, 118.	0.6	2
77	Modern-day prostate cancer is not meaningfully associated with lower urinary tract symptoms: Analysis of a propensity score-matched cohort. <i>Canadian Urological Association Journal</i> , 2017, 11, 41.	0.6	11
78	Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic. <i>Journal of Clinical Oncology</i> , 2017, 35, 2299-2305.	1.6	241
79	The association of male pattern baldness and risk of cancer and high-grade disease among men presenting for prostate biopsy. <i>Canadian Urological Association Journal</i> , 2016, 10, 424.	0.6	6
80	What's new bladder cancer research?. <i>Canadian Urological Association Journal</i> , 2016, 10, 134.	0.6	0
81	Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy. <i>Bladder Cancer</i> , 2016, 2, 263-272.	0.4	7
82	Treatment of bladder cancer in the elderly. <i>Investigative and Clinical Urology</i> , 2016, 57, S26.	2.0	28
83	Stricter Active Surveillance Criteria for Prostate Cancer do Not Result in Significantly Better Outcomes: A Comparison of Contemporary Protocols. <i>Journal of Urology</i> , 2016, 196, 1645-1650.	0.4	19
84	Dynamic interplay between locus-specific DNA methylation and hydroxymethylation regulates distinct biological pathways in prostate carcinogenesis. <i>Clinical Epigenetics</i> , 2016, 8, 32.	4.1	20
85	Identification of the best complete blood count-based predictors for bladder cancer outcomes in patients undergoing radical cystectomy. <i>British Journal of Cancer</i> , 2016, 114, 207-212.	6.4	53
86	Influence of Metabolic Syndrome on Prostate Cancer Stage, Grade, and Overall Recurrence Risk in Men Undergoing Radical Prostatectomy. <i>Urology</i> , 2016, 93, 77-85.	1.0	31
87	An Increase in Gleason 6 Tumor Volume While on Active Surveillance Portends a Greater Risk of Grade Reclassification with Further Followup. <i>Journal of Urology</i> , 2016, 195, 307-312.	0.4	9
88	Gender and Bladder Cancer: A Collaborative Review of Etiology, Biology, and Outcomes. <i>European Urology</i> , 2016, 69, 300-310.	1.9	460
89	A cancer specific hypermethylation signature of the TERT promoter predicts biochemical relapse in prostate cancer: a retrospective cohort study. <i>Oncotarget</i> , 2016, 7, 57726-57736.	1.8	55
90	The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. <i>Canadian Urological Association Journal</i> , 2016, 10, 25.	0.6	17

#	ARTICLE	IF	CITATIONS
91	Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series. <i>Prostate</i> , 2015, 75, 1277-1284.	2.3	47
92	Positive Surgical Margins: Race or Surgeon?. <i>European Urology</i> , 2015, 67, 458-459.	1.9	0
93	The effect of metformin on cancer-specific survival outcomes in diabetic patients undergoing radical cystectomy for urothelial carcinoma of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 386.e7-386.e13.	1.6	31
94	Impact of the U.S. Preventive Services Task Force Recommendations against Prostate Specific Antigen Screening on Prostate Biopsy and Cancer Detection Rates. <i>Journal of Urology</i> , 2015, 193, 1519-1524.	0.4	90
95	Renal Tumor Biopsy for Small Renal Masses: A Single-center 13-year Experience. <i>European Urology</i> , 2015, 68, 1007-1013.	1.9	238
96	Molecular and clinical support for a four-tiered grading system for bladder cancer based on the WHO 1973 and 2004 classifications. <i>Modern Pathology</i> , 2015, 28, 695-705.	5.5	37
97	Dissecting the Association Between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort. <i>European Urology</i> , 2015, 67, 64-70.	1.9	91
98	Health-related quality of life in robotic versus open radical prostatectomy. <i>Canadian Urological Association Journal</i> , 2015, 9, 179.	0.6	9
99	CUA guidelines on the management of non-muscle invasive bladder cancer. <i>Canadian Urological Association Journal</i> , 2015, 9, 690.	0.6	67
100	Treatment of muscle-invasive bladder cancer in Canada: A survey of genitourinary medical oncologists and urologists. <i>Canadian Urological Association Journal</i> , 2014, 8, 309.	0.6	12
101	Concordance between transrectal ultrasound guided biopsy results and radical prostatectomy final pathology: Are we getting better at predicting final pathology?. <i>Canadian Urological Association Journal</i> , 2014, 8, 47.	0.6	11
102	Obesity Is Associated With Larger Prostate Volume but not With Worse Urinary Symptoms: Analysis of a Large Multiethnic Cohort. <i>Urology</i> , 2014, 83, 81-87.	1.0	22
103	Regular Transition Zone Biopsy during Active Surveillance for Prostate Cancer May Improve Detection of Pathological Progression. <i>Journal of Urology</i> , 2014, 192, 1088-1093.	0.4	6
104	A Negative Confirmatory Biopsy Among Men on Active Surveillance for Prostate Cancer Does Not Protect Them from Histologic Grade Progression. <i>European Urology</i> , 2014, 66, 406-413.	1.9	36
105	The Impact of the Use of Aspirin and Other Nonsteroidal Anti-inflammatory Drugs on the Risk of Prostate Cancer Detection on Biopsy. <i>Urology</i> , 2014, 84, 1073-1080.	1.0	2
106	Obesity Is Associated with Risk of Progression for Low-risk Prostate Cancers Managed Expectantly. <i>European Urology</i> , 2014, 66, 841-848.	1.9	56
107	Next-generation RNA Sequencing of Archival Formalin-fixed Paraffin-embedded Urothelial Bladder Cancer. <i>European Urology</i> , 2014, 66, 982-986.	1.9	33
108	Prevalence of Inflammation and Benign Prostatic Hyperplasia on Autopsy in Asian and Caucasian Men. <i>European Urology</i> , 2014, 66, 619-622.	1.9	57



#	ARTICLE	IF	CITATIONS
109	FGFR3 mutations, but not FGFR3 expression and FGFR3 copy-number variations, are associated with favourable non-muscle invasive bladder cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2014, 465, 207-213.	2.8	23
110	Lean Methodology Improves Efficiency in Outpatient Academic Uro-oncology Clinics. <i>Urology</i> , 2014, 83, 992-998.	1.0	33
111	The Importance of Surgeon Characteristics on Impacting Oncologic Outcomes for Patients Undergoing Radical Cystectomy. <i>Journal of Urology</i> , 2014, 192, 714-720.	0.4	22
112	Urothelial Bladder Cancer Urinary Biomarkers. <i>Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine</i> , 2014, 25, 99-114.	0.7	5
113	Prevalence of prostate cancer across the globe: what can autopsy studies teach us about this peculiar disease?. <i>Archivos Espanoles De Urologia</i> , 2014, 67, 400-8.	0.2	3
114	Patients with Lynch Syndrome Mismatch Repair Gene Mutations Are at Higher Risk for Not Only Upper Tract Urothelial Cancer but Also Bladder Cancer. <i>European Urology</i> , 2013, 63, 379-385.	1.9	85
115	Demographic analysis of randomized controlled trials in bladder cancer. <i>BJU International</i> , 2013, 111, 419-426.	2.5	6
116	Upper urinary tract and urethral recurrences following radical cystectomy: review of risk factors and outcomes between centres with different follow-up protocols. <i>World Journal of Urology</i> , 2013, 31, 161-167.	2.2	28
117	Re: Genome Sequencing Identifies a Basis for Everolimus Sensitivity. <i>European Urology</i> , 2013, 64, 516.	1.9	7
118	Immediate Post-transurethral Resection of Bladder Tumor Intravesical Chemotherapy Prevents Non-muscle-invasive Bladder Cancer Recurrences: An Updated Meta-analysis on 2548 Patients and Quality-of-Evidence Review. <i>European Urology</i> , 2013, 64, 421-430.	1.9	122
119	Screening for Bladder Cancer: Rationale, Limitations, Whom to Target, and Perspectives. <i>European Urology</i> , 2013, 63, 1049-1058.	1.9	64
120	Neoadjuvant chemotherapy (NC) should be administered to fit patients with newly diagnosed, potentially resectable muscle-invasive urothelial cancer (MIUC) of the bladder – A 2013 CAGMO Consensus Statement and Call for a Streamlined Referral Process. <i>Canadian Urological Association Journal</i> , 2013, 7, 312.	0.6	18
121	Gender-specific effect of smoking on upper tract urothelial carcinoma outcomes. <i>BJU International</i> , 2013, 112, 623-637.	2.5	31
122	Prevalence of Prostate Cancer on Autopsy: Cross-Sectional Study on Unscreened Caucasian and Asian Men. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1050-1058.	6.3	208
123	Weighing the data on diet and prostate cancer. <i>Canadian Urological Association Journal</i> , 2013, 2, 516.	0.6	1
124	Oncologic outcomes following radical prostatectomy in the active surveillance era. <i>Canadian Urological Association Journal</i> , 2013, 7, 475.	0.6	15
125	The management of BCG failure in non-muscle-invasive bladder cancer: an update. <i>Canadian Urological Association Journal</i> , 2013, 3, 199.	0.6	85
126	Canadian Consensus Conference: The FDA decision on the use of 5ARIs. <i>Canadian Urological Association Journal</i> , 2012, 6, 83-88.	0.6	7



#	ARTICLE	IF	CITATIONS
127	Treatment Options Available for Bacillus Calmette-GuÃ©rin Failure in Non-muscle-invasive Bladder Cancer. <i>European Urology</i> , 2012, 62, 1088-1096.	1.9	67
128	Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. <i>Epigenetics</i> , 2012, 7, 1037-1045.	2.7	42
129	Sex differences in bladder cancer outcomes among smokers with advanced bladder cancer. <i>BJU International</i> , 2012, 109, 70-76.	2.5	22
130	A New and Highly Prognostic System to Discern T1 Bladder Cancer Substage. <i>European Urology</i> , 2012, 61, 378-384.	1.9	144
131	Limited, Extended, Superextended, Megaextended Pelvic Lymph Node Dissection at the Time of Radical Cystectomy: What Should We Perform?. <i>European Urology</i> , 2012, 61, 243-244.	1.9	20
132	To Biopsy or Not to Biopsy-You Shall Think Twice. <i>European Urology</i> , 2012, 61, 1115-1117.	1.9	14
133	Upstaging of urothelial cancer at the time of radical cystectomy: factors associated with upstaging and its effect on outcome. <i>BJU International</i> , 2012, 110, 804-811.	2.5	96
134	Prognostic value of molecular markers, substage and European Organisation for the Research and Treatment of Cancer risk scores in primary T1 bladder cancer. <i>BJU International</i> , 2012, 110, 1169-1176.	2.5	53
135	Does patient age affect survival after radical cystectomy?. <i>BJU International</i> , 2012, 110, E486-93.	2.5	28
136	Impact of multiparametric endorectal coil prostate MRI on disease reclassification among active surveillance candidates: A prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2012, 30, 30-30.	1.6	1
137	Association of tumor hypoxia with lower survival after radiotherapy for muscle-invasive bladder cancer.. <i>Journal of Clinical Oncology</i> , 2012, 30, 292-292.	1.6	0
138	What is the future of virtual cystoscopy in urology?. <i>Canadian Urological Association Journal</i> , 2011, 5, 38-39.	0.6	6
139	Chemoprevention of prostate cancer: is there evidence from clinical trials?. <i>Clinical Investigation</i> , 2011, 1, 1257-1268.	0.0	1
140	Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-GuÃ©rin treatment. <i>BJU International</i> , 2011, 107, 540-546.	2.5	37
141	Loss of androgen receptor expression is not associated with pathological stage, grade, gender or outcome in bladder cancer: a large multi-institutional study. <i>BJU International</i> , 2011, 108, 24-30.	2.5	111
142	Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort. <i>BJU International</i> , 2011, 108, E237-E244.	2.5	62
143	Impact of 5 $\alpha$ -Reductase Inhibitors on Men Followed by Active Surveillance for Prostate Cancer. <i>European Urology</i> , 2011, 59, 509-514.	1.9	52
144	Select Screening in a Specific High-Risk Population of Patients Suggests a Stage Migration Toward Detection of Non-muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2011, 59, 1026-1031.	1.9	51

#	ARTICLE	IF	CITATIONS
145	Urine Markers for Detection and Surveillance of Non-muscle-Invasive Bladder Cancer. <i>European Urology</i> , 2011, 60, 484-492.	1.9	176
146	Prostate-specific antigen test result interpretation when combined with risk factors for recommendation of biopsy: a survey of urologists' practice patterns. <i>International Urology and Nephrology</i> , 2011, 43, 31-37.	1.4	3
147	Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCare <sup>Bladder</sup> ): a randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2011, 18, 835-841.	4.4	10
148	Long-term prognostic value of the combination of EORTC risk group calculator and molecular markers in non-muscle-invasive bladder cancer patients treated with intravesical Bacille Calmette-Guérin. <i>Urology Annals</i> , 2011, 3, 119.	0.6	23
149	Pathological stage review is indicated in primary pT1 bladder cancer. <i>BJU International</i> , 2010, 106, 206-211.	2.5	46
150	An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously) T1 High-grade Bladder Cancer. <i>Overlook 10</i>	1.9	169
151	The Pathologist's Mean Grade Is Constant and Individualizes the Prognostic Value of Bladder Cancer Grading. <i>European Urology</i> , 2010, 57, 1052-1057.	1.9	65
152	A Critical Analysis of Orthotopic Bladder Substitutes in Adult Patients with Bladder Cancer: Is There a Perfect Solution?. <i>European Urology</i> , 2010, 58, 374-383.	1.9	52
153	Re: A Sequence Variant at 4p16.3 Confers Susceptibility to Urinary Bladder Cancer. <i>European Urology</i> , 2010, 58, 943-944.	1.9	0
154	Prostatic evasive anterior tumours: the role of magnetic resonance imaging. <i>BJU International</i> , 2010, 105, 1231-1236.	2.5	171
155	Does nerve-sparing radical prostatectomy increase the risk of positive surgical margins and biochemical progression?. <i>Urology Annals</i> , 2010, 2, 58.	0.6	9
156	Optimal timing of radical cystectomy in T1 high-grade bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1891-1902.	2.4	8
157	Clinical significance of the positive surgical margin based upon location, grade, and stage. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 197-204.	1.6	33
158	Staging and Staging Errors in Bladder Cancer. <i>European Urology Supplements</i> , 2010, 9, 2-9.	0.1	53
159	Lymphadenectomy in the Surgical Management of Penile Cancer. <i>European Urology</i> , 2009, 55, 1075-1088.	1.9	201
160	Recurrence and Progression of Disease in Non-muscle-Invasive Bladder Cancer: From Epidemiology to Treatment Strategy. <i>European Urology</i> , 2009, 56, 430-442.	1.9	584
161	Prostate cancer: a serious disease suitable for prevention. <i>BJU International</i> , 2009, 103, 864-870.	2.5	38
162	The fate of an unsatisfactory urine cytology test among patients with urothelial carcinoma. <i>BJU International</i> , 2009, 104, 1641-1645.	2.5	2

#	ARTICLE	IF	CITATIONS
163	Focal Therapy Will Be the Future Treatment Modality: The Motion "Con", European Urology Supplements, 2009, 8, 433-438.	0.1	3
164	Late Onset of Bladder Urothelial Carcinoma After Kidney Transplantation for End-Stage Aristolochic Acid Nephropathy: A Case Series With 15-Year Follow-up. American Journal of Kidney Diseases, 2008, 51, 471-477.	1.9	99
165	The REDUCE trial: chemoprevention in prostate cancer using a dual 5 $\alpha$ -reductase inhibitor, dutasteride. Expert Review of Anticancer Therapy, 2008, 8, 1073-1079.	2.4	33
166	Predictive Value of Plasma Hepatocyte Growth Factor/Scatter Factor Levels in Patients with Clinically Localized Prostate Cancer. Clinical Cancer Research, 2008, 14, 7385-7390.	7.0	47
167	Tamsulosin oral controlled absorption system (OCAS) in the treatment of benign prostatic hypertrophy. Therapeutics and Clinical Risk Management, 2008, Volume 4, 11-18.	2.0	8
168	Prostate cancer prevention. Cancer, 2007, 110, 1889-1899.	4.1	60
169	Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Modern Pathology, 2007, 20, 445-459.	5.5	128
170	The medical management of prostate cancer: a multidisciplinary team approach. BJU International, 2007, 99, 22-27.	2.5	36
171	Laparoscopic Partial Nephrectomy with "On-Demand" Clamping Reduces Warm Ischemia Time. European Urology, 2007, 52, 804-810.	1.9	82
172	Extended and Saturation Prostatic Biopsy in the Diagnosis and Characterisation of Prostate Cancer: A Critical Analysis of the Literature. European Urology, 2007, 52, 1309-1322.	1.9	292
173	When and How to Treat Superficial and Muscle-Invasive Bladder Cancer. European Urology, 2007, 52, 1554-1557.	1.9	3
174	Hormone Therapy: Improving Therapy Decisions and Monitoring. European Urology Supplements, 2006, 5, 369-376.	0.1	9
175	How do I treat and follow my TUNA patients. World Journal of Urology, 2006, 24, 397-404.	2.2	13
176	Auto-Antibody Signatures in Prostate Cancer. European Urology, 2006, 49, 410-411.	1.9	1
177	Prostate Size and Risk of High-Grade, Advanced Prostate Cancer and Biochemical Progression after Radical Prostatectomy: A Search Database Study. European Urology, 2006, 49, 757-758.	1.9	87
178	Random Biopsies in Bladder Tumors: In Most Cases, You Shall Not!. European Urology, 2006, 50, 186-193.	1.9	1
179	Immediate versus deferred androgen-deprivation therapy for prostate cancer: the jury is still out. Nature Reviews Urology, 2006, 3, 474-475.	1.4	1
180	Pharmacotherapy for prostate cancer, with emphasis on hormonal treatments. Expert Opinion on Pharmacotherapy, 2006, 7, 1685-1699.	1.8	6

#	ARTICLE	IF	CITATIONS
181	Hormonal therapy options for prostate-specific antigen-only recurrence of prostate cancer after previous local therapy. <i>BJU International</i> , 2005, 95, 285-290.	2.5	6
182	Modified specimen retrieval facilitates urethro-vesical anastomosis in laparoscopic radical prostatectomy. <i>BJU International</i> , 2005, 95, 447-449.	2.5	1
183	Evaluation of Male Sexual Function in Patients with Lower Urinary Tract Symptoms (LUTS) Associated with Benign Prostatic Hyperplasia (BPH) Treated with a Phytotherapeutic Agent (Permixon®), Tamsulosin or Finasteride. <i>European Urology</i> , 2005, 48, 269-276.	1.9	66
184	Quality of Life after Radical Prostatectomy: How to Preserve Potency?. <i>European Urology Supplements</i> , 2005, 4, 2-7.	0.1	5
185	The role of luteinizing hormone-releasing hormone therapy in locally advanced prostate cancer and biochemical failure: considerations for optimal use. <i>Clinical Therapeutics</i> , 2005, 27, 273-285.	2.5	4
186	Urinary/serum prostate-specific antigen ratio: Comparison with free/total serum prostate-specific antigen ratio in improving prostate cancer detection. <i>Urology</i> , 2005, 65, 533-537.	1.0	27
187	Prognosis of T1G3 Tumors: Clinical Factors. <i>European Urology Supplements</i> , 2004, 3, 73-78.	0.1	8
188	Is Seminal Vesicle Ablation Mandatory for All Patients Undergoing Radical Prostatectomy?. <i>European Urology</i> , 2004, 46, 42-49.	1.9	45
189	Radical prostatectomy: a prospective comparison of oncological and functional results between open and laparoscopic approaches. <i>World Journal of Urology</i> , 2003, 20, 360-366.	2.2	142
190	PSA Progression Following Radical Prostatectomy and Radiation Therapy: New Standards in the New Millennium. <i>European Urology</i> , 2003, 43, 12-27.	1.9	73
191	Long-Term Evaluation of Transurethral Needle Ablation of the Prostate (TUNA) for Treatment of Symptomatic Benign Prostatic Hyperplasia: Clinical Outcome up to Five Years from Three Centers. <i>European Urology</i> , 2003, 44, 89-93.	1.9	102
192	An artificial neural network to predict the outcome of repeat prostate biopsies. <i>Urology</i> , 2003, 62, 456-460.	1.0	69
193	The need to embrace molecular profiling of tumor cells in prostate and bladder cancer. <i>Clinical Cancer Research</i> , 2003, 9, 1240-7.	7.0	11
194	Minimally invasive therapies for benign prostatic hyperplasia in the new millennium: long-term data. <i>Current Opinion in Urology</i> , 2002, 12, 7-14.	1.8	22
195	Complexed prostate-specific antigen, complexed prostate-specific antigen density of total and transition zone, complexed/total prostate-specific antigen ratio, free-to-total prostate-specific antigen ratio, density of total and transition zone prostate-specific antigen: results of the prospective multicenter European trial. <i>Urology</i> , 2002, 60, 4-9.	1.0	215
196	Computerised Assessment of Maximum Urinary Flow: an Efficient, Consistent and Valid Approach. <i>European Urology</i> , 2002, 41, 206-213.	1.9	2
197	Repeat Prostate Biopsy: Who, How and When?. <i>European Urology</i> , 2002, 42, 93-103.	1.9	109
198	Comparison of laparoscopic radical prostatectomy techniques. <i>Current Urology Reports</i> , 2002, 3, 148-151.	2.2	19

#	ARTICLE	IF	CITATIONS
199	Can survival be prolonged for patients with hormone-resistant prostate cancer?. <i>Lancet</i> , The, 2001, 357, 326-327.	13.7	15
200	4&ndash;Year Follow&ndash;Up Results of a European Prospective Randomized Study on Neoadjuvant Hormonal Therapy prior to Radical Prostatectomy in T2&ndash;3N0M0 Prostate Cancer. <i>European Urology</i> , 2000, 38, 706-713.	1.9	227
201	What are the immunologically active components of Bacille Calmette-GuÃ©rin in therapy of superficial bladder cancer?. <i>International Journal of Cancer</i> , 2000, 87, 844-852.	5.1	61
202	Neoadjuvant and adjuvant hormone therapy for prostate cancer. <i>World Journal of Urology</i> , 2000, 18, 179-182.	2.2	7
203	BIOLOGICAL MARKERS IN SUPERFICIAL BLADDER TUMORS AND THEIR PROGNOSTIC SIGNIFICANCE. <i>Urologic Clinics of North America</i> , 2000, 27, 179-189.	1.8	35
204	Laparoscopic partial bladder resection for bladder endometriosis. <i>Gynaecological Endoscopy</i> , 1999, 8, 11-15.	0.4	1
205	PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL. <i>Urology</i> , 1999, 54, 517-522.	1.0	152
206	Total and transition zone prostate volume and age: how do they affect the utility of PSA-based diagnostic parameters for early prostate cancer detection?. <i>Urology</i> , 1999, 54, 846-852.	1.0	75
207	Radiofrequency Interstitial Tumor Ablation (RITA) Is a Possible New Modality for Treatment of Renal Cancer: <i>Ex Vivo</i> and <i>in Vivo</i> Experience. <i>Journal of Endourology</i> , 1997, 11, 251-258.	2.1	366
208	Transperineal radiofrequency interstitial tumor ablation of the prostate: Correlation of magnetic resonance imaging with histopathologic examination. <i>Urology</i> , 1997, 50, 986-993.	1.0	85
209	Is one single prostate biopsy helpful for choosing a medical treatment of benign prostatic hyperplasia? a quantitative computerized morphometric study. <i>Urology</i> , 1996, 47, 329-334.	1.0	22
210	Transurethral needle ablation of the prostate. <i>Current Opinion in Urology</i> , 1995, 5, 35-38.	1.8	17
211	Transurethral needle ablation of the prostate for treatment of benign prostatic hyperplasia: Early clinical experience. <i>Urology</i> , 1995, 45, 28-33.	1.0	116
212	Transurethral Needle Ablation (TUNA): Safety, Feasibility, and Tolerance of a New Office Procedure for Treatment of Benign Prostatic Hyperplasia. <i>European Urology</i> , 1993, 24, 415-423.	1.9	114
213	Transurethral Needle Ablation (TUNA): Thermal Gradient Mapping and Comparison of Lesion Size in a Tissue Model and in Patients with Benign Prostatic Hyperplasia. <i>European Urology</i> , 1993, 24, 411-414.	1.9	52